Bionano Genomics, Inc. (BNGO) stock
Close on Nov 17, 2026Market cap $11.21MP/E –Yield –
Bionano Genomics, Inc. grew revenue 10.0% to $30.18M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $11.21M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.21M
- P/E ratio
- –
- Price to sales
- 0.37
- Price to book
- 0.35
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $30.18M
- Net income
- -$32.16M
- EPS, diluted
- -$3.76
- Book value per share
- $2.74
- Diluted shares
- 12M
Trading
- Next earnings
- Mar 22, 2027 (estimated, during market hours)
- Previous close
- $0.94
- Open
- $0.95
- Day's range
- $0.95 – $0.97
- Volume
- 72,847
- Average volume (20 days)
- 257,273
- 52-week range
- $0.93 – $2.23
- RSI (14 days)
- 31.2
- Volatility (1 year)
- 64.0%
- Relative volume
- 0.10×
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | BNGO | S&P 500 | Difference | BNGO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.8% | -4.0% | −19.8 pts | ||
| 3 months | -20.0% | -5.0% | −15.0 pts | ||
| Year to date | -37.8% | +8.2% | −46.0 pts | ||
| 1 year | -36.5% | +11.2% | −47.7 pts | ||
| 3 years | -98.8% | +68.5% | −167.3 pts | -77.3% | +19.0% |
| 5 years | -100.0% | +67.3% | −167.2 pts | -79.8% | +10.8% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bionano Genomics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- News
- Results
About Bionano Genomics
Laboratory Analytical Instruments
Bionano Genomics, Inc. is a life sciences company that provides optical genome mapping solutions for genomic analysis and cytogenetic research. The company offers imaging instruments, notably the Saphyr and Stratys systems, along with related consumables, testing services, and VIA data analysis software. It conducts business through a single reportable segment and operates subsidiaries including BioDiscovery, Purigen Biosystems, and Lineagen, which operates as Bionano Laboratories. Its customers include researchers, cytogeneticists, and laboratories performing routine genomic analysis.
Company profile, executives and historyBionano Genomics stock: common questions
What is Bionano Genomics's stock price?
BNGO closed at $0.95 on Nov 17, 2026, up 1.29% on the day. Over the past 52 weeks it traded between $0.93 and $2.23.
What is Bionano Genomics's market cap?
Bionano Genomics was worth $11.21M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is BNGO's P/E ratio?
Bionano Genomics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.76), so it has no meaningful P/E ratio.
How much revenue does Bionano Genomics make?
Bionano Genomics reported revenue of $30.18M for the twelve months to Jun 30, 2026, up 10.0% from a year earlier.
Does Bionano Genomics pay a dividend?
No. Bionano Genomics has not paid a cash dividend over the last twelve months.
When does Bionano Genomics report earnings next?
Bionano Genomics is expected to report Q4 FY2026 results on Mar 22, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has BNGO stock performed over the past year?
Including dividends, BNGO returned -36.5% over the past year, against +11.2% for the S&P 500.
How many BNGO shares are sold short?
1M shares were sold short at the latest FINRA report, 12.00% of the float, or 7.4 days of average trading volume.
Who are Bionano Genomics's competitors?
Companies most similar to Bionano Genomics by business, industry and size include SEER, RPID, PACB, PRPO, HBIO.
See a number that looks wrong?